{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:43:08Z","timestamp":1789746188973,"version":"4.0.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) can cause cardiac immune-related adverse events (irAEs), including pericarditis. Cardiovascular events related to pericardial irAE are less frequent, but fulminant forms can be fatal. However, the diagnosis and treatment strategies for pericardial irAE have not established.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 58-year-old man was diagnosed with advanced non-small-cell lung cancer and nivolumab was administered as 5th-line therapy. Eighteen months after the initiation of nivolumab, the patient developed limb oedema and increased body weight. Although a favourable response of the cancer was observed, pericardial thickening and effusion were newly detected. He was diagnosed with irAE pericarditis after excluding other causes of pericarditis. Nivolumab was suspended and a high-dose corticosteroid was initiated. However, right heart failure (RHF) symptoms were exacerbated during the tapering of corticosteroid because acute pericarditis developed to steroid-refractory constrictive pericarditis. To suppress sustained inflammation of the pericardium, infliximab, a tumour necrosis factor-alfa inhibitor, was initiated. After the initiation of infliximab, the corticosteroid dose was tapered without deterioration of RHF. Exacerbation of lung cancer by irAE treatment including infliximab was not observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>IrAE should be considered when pericarditis develops after the administration of ICI even after a long period from its initiation. Infliximab rescue therapy may be considered as a 2nd-line therapy for steroid-refractory irAE pericarditis even with constrictive physiology.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytab002","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T13:50:43Z","timestamp":1612187443000},"source":"Crossref","is-referenced-by-count":23,"title":["Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-175X","authenticated-orcid":false,"given":"Shohei","family":"Moriyama","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-6054","authenticated-orcid":false,"given":"Mitsuhiro","family":"Fukata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoma","family":"Tatsumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Onco-Cardiology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"2021062103290827100_ytab002-B1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021062103290827100_ytab002-B2","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021062103290827100_ytab002-B3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021062103290827100_ytab002-B4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2021062103290827100_ytab002-B5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2021062103290827100_ytab002-B6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","article-title":"Pericardial effusion under nivolumab: case-reports and review of the literature","volume":"7","author":"Saade","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2021062103290827100_ytab002-B7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2021062103290827100_ytab002-B8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jacc.2007.09.039","article-title":"Constrictive pericarditis in the modern era","volume":"51","author":"Talreja","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2021062103290827100_ytab002-B9","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021062103290827100_ytab002-B10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"2021062103290827100_ytab002-B11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: a comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"World J Clin Cases"},{"key":"2021062103290827100_ytab002-B12","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/1\/ytab002\/38710129\/ytab002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/1\/ytab002\/38710129\/ytab002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T03:29:17Z","timestamp":1624246157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytab002\/6125231"}},"subtitle":[],"editor":[{"given":"Matteo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Rami Riziq","family":"Yousef Abumuaileq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Constantinos","family":"Bakogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Stefan","family":"Simovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Ross","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytab002","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2021,1]]},"article-number":"ytab002"}}